Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. announced that it will receive CNY 600,000,000 in an equity round of funding from existing investor, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SEHK:874) on January 4, 2017. Post transaction, the company will retain 100% stake in the company. The registered capital of the company will increase from CNY 26,494,000 to CNY 626,494,000. The transaction will take place in tranches. As part of the first tranche, the company will receive CNY 82,800,500 from Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SEHK:874). The remaining CNY 517,199,500 will be authorized by the company board of directors which will be decided based on the project implementation progress situation. The transaction was approved at the 15th session of the 6th supervisory board meeting and 28th session of the 6th directorate meeting of the investor and does not require the approval of its shareholders.